|
ATE205202T1
(de)
|
1992-03-13 |
2001-09-15 |
Merck Sharp & Dohme |
Imidazol-, triazol- und tetrazolderivate
|
|
GB9207396D0
(en)
|
1992-04-03 |
1992-05-13 |
Merck Sharp & Dohme |
Therapeutic agents
|
|
US5952294A
(en)
|
1996-07-31 |
1999-09-14 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Peptidyl prodrugs and methods of making and using the same
|
|
JP4109123B2
(ja)
|
2001-05-09 |
2008-07-02 |
セルメド オンコロジー （ユーエスエイ）， インコーポレイテッド |
ペプチドデホルミラーゼ活性化プロドラッグ
|
|
US6642390B2
(en)
|
2001-07-11 |
2003-11-04 |
Lexicon Pharmaceuticals, Inc. |
One step synthesis of 1,2,3-triazole carboxylic acids
|
|
JP4299139B2
(ja)
|
2001-12-18 |
2009-07-22 |
メルク エンド カムパニー インコーポレーテッド |
代謝型グルタミン酸受容体−５のヘテロアリール置換トリアゾールモジュレータ
|
|
WO2003090751A1
(en)
|
2002-04-26 |
2003-11-06 |
Pfizer Products Inc. |
Pyrimidine-2, 4, 6-trione metallo-proteinase inhibitors
|
|
US7354938B2
(en)
*
|
2004-03-23 |
2008-04-08 |
Amgen Inc. |
Pyrazole compounds and uses related thereto
|
|
TWI309240B
(en)
|
2004-09-17 |
2009-05-01 |
Hoffmann La Roche |
Anti-ox40l antibodies
|
|
ZA200707482B
(en)
|
2005-02-04 |
2008-12-31 |
Senomyx Inc |
Compounds comprising linked heteroaryl moieties and their use as novel umami flavour modifiers, tastants and taste enhancers for comestible compositions
|
|
WO2006091898A2
(en)
*
|
2005-02-25 |
2006-08-31 |
Adenosine Therapeutics, Llc |
Pyrazolyl substituted xanthines
|
|
EP1866339B8
(en)
|
2005-03-25 |
2021-12-01 |
GITR, Inc. |
Gitr binding molecules and uses therefor
|
|
KR101607288B1
(ko)
|
2005-07-01 |
2016-04-05 |
이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. |
예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
|
|
NZ571324A
(en)
*
|
2006-03-17 |
2011-07-29 |
Gilead Palo Alto Inc |
Method of preventing and treating hepatic disease using A2B adenoise receptor antagonists
|
|
EP2041115A4
(en)
|
2006-07-04 |
2010-07-07 |
Astrazeneca Ab |
NEW PYRIDINE ANALOG
|
|
US7994321B2
(en)
|
2006-08-08 |
2011-08-09 |
Hoffmann-La Roche Inc. |
Substituted thieno[3,2-C]pyridine-7-carboxylic acid derivatives
|
|
EP1987839A1
(en)
|
2007-04-30 |
2008-11-05 |
I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale |
Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
|
|
EP2175884B8
(en)
|
2007-07-12 |
2017-02-22 |
GITR, Inc. |
Combination therapies employing gitr binding molecules
|
|
EP2044949A1
(en)
|
2007-10-05 |
2009-04-08 |
Immutep |
Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
|
|
JP2011511778A
(ja)
|
2008-01-30 |
2011-04-14 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション |
エステルに基づいたペプチドプロドラッグ
|
|
PE20091953A1
(es)
|
2008-05-08 |
2010-01-09 |
Du Pont |
Azoles sustituidos como fungicidas
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
US9643922B2
(en)
|
2008-08-18 |
2017-05-09 |
Yale University |
MIF modulators
|
|
BRPI0917394A2
(pt)
|
2008-08-18 |
2019-09-24 |
Univ Yale |
moduladores de mif
|
|
TWI729512B
(zh)
|
2008-12-09 |
2021-06-01 |
美商建南德克公司 |
抗pd-l1抗體及其於增進t細胞功能之用途
|
|
CN102388037B
(zh)
*
|
2009-02-10 |
2014-12-03 |
詹森药业有限公司 |
作为脯氨酰羟化酶抑制剂的喹唑啉酮
|
|
WO2010108187A2
(en)
|
2009-03-20 |
2010-09-23 |
Brandeis University |
Compounds and methods for treating mammalian gastrointestinal microbial infections
|
|
WO2010144780A1
(en)
|
2009-06-12 |
2010-12-16 |
University Of Kansas |
Compositions and methods for establishing and maintaining stem cells in an undifferentiated state
|
|
WO2011005806A1
(en)
|
2009-07-08 |
2011-01-13 |
Isp Investments Inc. |
4- and 5 substituted 1,2,3- triazole moieties with at least one remote polymerizable moiety and polymers thereof
|
|
CN102574924A
(zh)
|
2009-09-03 |
2012-07-11 |
先灵公司 |
抗-gitr抗体
|
|
WO2011050284A1
(en)
*
|
2009-10-23 |
2011-04-28 |
Glaxosmithkline Llc |
Pyrazolylpyridine antiviral agents
|
|
PT2949670T
(pt)
|
2009-12-10 |
2019-05-20 |
Hoffmann La Roche |
Anticorpos que se ligam preferencialmente ao domínio extracelular 4 do csf1r e respetiva utilização
|
|
US20130030359A1
(en)
|
2010-01-22 |
2013-01-31 |
Ascendis Pharma A/S |
Dipeptide-based prodrug linkers for aromatic amine-containing drugs
|
|
JP6026284B2
(ja)
|
2010-03-03 |
2016-11-16 |
プロビオドルグ エージー |
グルタミニルシクラーゼの阻害剤
|
|
NZ705128A
(en)
|
2010-03-04 |
2015-04-24 |
Macrogenics Inc |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
|
WO2011107553A1
(en)
|
2010-03-05 |
2011-09-09 |
F. Hoffmann-La Roche Ag |
Antibodies against human csf-1r and uses thereof
|
|
CA2789071C
(en)
|
2010-03-05 |
2018-03-27 |
F. Hoffmann-La Roche Ag |
Antibodies against human csf-1r and uses thereof
|
|
CN110269856A
(zh)
|
2010-03-30 |
2019-09-24 |
维颂公司 |
多取代芳族化合物作为凝血酶的抑制剂
|
|
CN107011438B
(zh)
|
2010-05-04 |
2020-11-20 |
戊瑞治疗有限公司 |
结合csf1r的抗体
|
|
SG10201912092VA
(en)
|
2010-09-09 |
2020-02-27 |
Pfizer |
4-1bb binding molecules
|
|
US8748435B2
(en)
*
|
2011-04-01 |
2014-06-10 |
Novartis Ag |
Pyrazolo pyrimidine derivatives
|
|
DK2699264T3
(en)
|
2011-04-20 |
2018-06-25 |
Medimmune Llc |
ANTIBODIES AND OTHER MOLECULES BINDING B7-H1 AND PD-1
|
|
KR101981873B1
(ko)
|
2011-11-28 |
2019-05-23 |
메르크 파텐트 게엠베하 |
항-ｐｄ-ｌ1 항체 및 그의 용도
|
|
WO2013085890A1
(en)
|
2011-12-06 |
2013-06-13 |
Glaxo Group Limited |
Therapeutic methods
|
|
RU2658603C2
(ru)
|
2011-12-15 |
2018-06-21 |
Ф.Хоффманн-Ля Рош Аг |
Антитела против человеческого csf-1r и их применения
|
|
CA2861122A1
(en)
|
2012-02-06 |
2013-08-15 |
Genentech, Inc. |
Compositions and methods for using csf1r inhibitors
|
|
PL2820006T3
(pl)
*
|
2012-02-29 |
2018-02-28 |
Chemocentryx, Inc. |
Benzosulfonamidy pirazolo-1-ilowe jako antagoniści CCR9
|
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
|
DE102012102162A1
(de)
|
2012-03-14 |
2013-09-19 |
Westfälische Wilhelms-Universität Münster Körperschaft des öffentlichen Rechts |
Ionenleitende polymere Verbindung für elektrochemische Zellen
|
|
AU2012374617B2
(en)
|
2012-05-11 |
2015-09-17 |
Five Prime Therapeutics, Inc. |
Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)
|
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
|
SG10201906328RA
(en)
|
2012-08-31 |
2019-08-27 |
Five Prime Therapeutics Inc |
Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
|
|
US9365527B2
(en)
|
2013-03-14 |
2016-06-14 |
Epizyme, Inc. |
Arginine methyltransferase inhibitors and uses thereof
|
|
CN105873577B
(zh)
|
2013-08-30 |
2019-06-18 |
西奈山伊坎医学院 |
环插烯酰胺作为溴结构域抑制剂
|
|
EP2903044A1
(de)
|
2014-02-04 |
2015-08-05 |
cynora GmbH |
Organische Moleküle zur Verwendung in optoelektronischen Bauelementen
|
|
US10052332B2
(en)
|
2014-04-29 |
2018-08-21 |
Emory University |
Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto
|
|
US20160251341A1
(en)
|
2015-02-27 |
2016-09-01 |
Verseon Corporation |
Substituted triazole compounds as serine protease inhibitors
|
|
EP3347008B1
(en)
|
2015-09-11 |
2022-03-09 |
Venatorx Pharmaceuticals, Inc. |
Beta-lactamase inhibitors
|
|
MX389798B
(es)
|
2017-01-20 |
2025-03-20 |
Arcus Biosciences Inc |
Azolopirimidina para el tratamiento de trastornos relacionados con el cáncer.
|
|
US11045472B2
(en)
|
2017-05-05 |
2021-06-29 |
Arcus Biosciences, Inc. |
Quinazoline-pyridine derivatives for the treatment of cancer-related disorders
|